Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by BTC Capital Management Inc.

BTC Capital Management Inc. grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 9.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,653 shares of the specialty pharmaceutical company's stock after buying an additional 4,271 shares during the period. BTC Capital Management Inc. owned 0.08% of Jazz Pharmaceuticals worth $6,115,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in JAZZ. Wedge Capital Management L L P NC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth about $32,497,000. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Cinctive Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock valued at $19,394,000 after buying an additional 100,112 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Jazz Pharmaceuticals by 47.7% during the third quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company's stock valued at $29,945,000 after buying an additional 86,768 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,253 shares of company stock valued at $890,594. 4.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on JAZZ shares. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. Needham & Company LLC reiterated a "buy" rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Piper Sandler reiterated an "overweight" rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Stock Down 0.3 %

Jazz Pharmaceuticals stock traded down $0.36 during midday trading on Tuesday, hitting $121.61. 323,627 shares of the stock were exchanged, compared to its average volume of 494,104. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $7.35 billion, a P/E ratio of 17.13, a P/E/G ratio of 0.90 and a beta of 0.56. The company has a 50 day moving average price of $122.69 and a two-hundred day moving average price of $116.10.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.